open access

Vol 13, No 5 (2017)
Review paper
Published online: 2017-11-15
Get Citation

Abiraterone acetate in the treatment of patients with metastatic prostate cancer

Piotr Wysocki
DOI: 10.5603/OCP.2017.0028
·
Oncol Clin Pract 2017;13(5):220-224.

open access

Vol 13, No 5 (2017)
REVIEW ARTICLES
Published online: 2017-11-15

Abstract

For a long time, systemic treatment of patients diagnosed with metastatic castration-resistant prostate cancer
(mCRPC) has been based solely on chemotherapy (docetaxel). The introduction of novel endocrine agents has
significantly improved outcomes of mCRPC patients. Till date, abirateron acetate is the only drug with confirmed
activity (significant improvement in overall survival) in both clinical settings: castration resistance (pre or post
chemotherapy) and castration sensitivity. The article is aimed to summarize current knowledge on the place and
role of abiraterone acetate in palliative systemic treatment of metastatic prostate cancer patients.

Abstract

For a long time, systemic treatment of patients diagnosed with metastatic castration-resistant prostate cancer
(mCRPC) has been based solely on chemotherapy (docetaxel). The introduction of novel endocrine agents has
significantly improved outcomes of mCRPC patients. Till date, abirateron acetate is the only drug with confirmed
activity (significant improvement in overall survival) in both clinical settings: castration resistance (pre or post
chemotherapy) and castration sensitivity. The article is aimed to summarize current knowledge on the place and
role of abiraterone acetate in palliative systemic treatment of metastatic prostate cancer patients.

Get Citation

Keywords

prostate cancer; abiraterone; castration resistance; metastases; endocrine treatment

About this article
Title

Abiraterone acetate in the treatment of patients with metastatic prostate cancer

Journal

Oncology in Clinical Practice

Issue

Vol 13, No 5 (2017)

Article type

Review paper

Pages

220-224

Published online

2017-11-15

DOI

10.5603/OCP.2017.0028

Bibliographic record

Oncol Clin Pract 2017;13(5):220-224.

Keywords

prostate cancer
abiraterone
castration resistance
metastases
endocrine treatment

Authors

Piotr Wysocki

References (22)
  1. Tannock I, Wit Rde, Berry W, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 2004; 351(15): 1502–1512.
  2. Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011; 29(16): 2191–2198.
  3. Kelly WK, Halabi S, Carducci MK, et al. Alliance for Clinical Trials in Oncology. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012; 30(13): 1534–1540.
  4. Fizazi K, Fizazi KS, Higano CS, et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013; 31(14): 1740–1747.
  5. Tannock IF, Fizazi K, Ivanov S, et al. VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013; 14(8): 760–768.
  6. Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013; 14(13): 1307–1316.
  7. Harris KA, Weinberg V, Bok RA, et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002; 168(2): 542–545.
  8. Ryan CJ, Weinberg V, Rosenberg J, et al. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007; 178(6): 2372–6; discussion 2377.
  9. de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21): 1995–2005.
  10. Fizazi K, Scher HI, Molina A, et al. COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13(10): 983–992.
  11. Harland S, Staffurth J, Molina A, et al. COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013; 49(17): 3648–3657.
  12. Ryan CJ, Smith MR, de Bono JS, et al. COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368(2): 138–148.
  13. Ryan CJ, Smith MR, Fizazi K, et al. COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16(2): 152–160.
  14. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013; 14(12): 1193–1199.
  15. Scott E, Sweeney CJ, Chen YH, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015; 373(8): 737–746.
  16. James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387(10024): 1163–1177.
  17. Vale CL, Burdett S, Rydzewska LHM, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. The Lancet Oncology. 2016; 17(2): 243–256.
  18. Fizazi K, Tran N, Fein L, et al. LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017; 377(4): 352–360.
  19. James ND, de Bono JS, Spears MR, et al. STAMPEDE Investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. 2017; 377(4): 338–351.
  20. Fizazi K, Flaig TW, Stöckle M, et al. Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. Ann Oncol. 2016; 27(4): 699–705.
  21. Parimi V, Goyal R, Poropatich K, et al. Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol. 2014; 2(4): 273–285.
  22. Vlachostergios PJ, Papandreou CN. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol. 2015; 5: 6.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl